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Abstract
Purpose The Zilver PTX drug-eluting stent (Cook Ireland
Ltd., Limerick, Ireland) represents an advance in endo-
vascular treatments for atherosclerotic superficial femoral
artery (SFA) disease. Clinical data demonstrate improved
clinical outcomes compared to bare-metal stents (BMS).
This analysis assessed the likely impact on the French
public health care budget of introducing reimbursement for
the Zilver PTX stent.
Methods A model was developed in Microsoft Excel to
estimate the impact of a progressive transition from BMS
to Zilver PTX over a 5-year horizon. The number of
patients undergoing SFA stenting was estimated on the
basis of hospital episode data. The analysis from the payer
perspective used French reimbursement tariffs. Target
lesion revascularization (TLR) after primary stent place-
ment was the primary outcome. TLR rates were based on
2-year data from the Zilver PTX single-arm study (6 and
9 %) and BMS rates reported in the literature (average 16
and 22 %) and extrapolated to 5 years. Net budget impact
was expressed as the difference in total costs (primary
stenting and reinterventions) for a scenario where BMS
is progressively replaced by Zilver PTX compared to a
scenario of BMS only.
Results The model estimated a net cumulative 5-year
budget reduction of €6,807,202 for a projected population
of 82,316 patients (21,361 receiving Zilver PTX). Base
case results were confirmed in sensitivity analyses.
Conclusion Adoption of Zilver PTX could lead to
important savings for the French public health care payer.
Despite higher initial reimbursement for the Zilver PTX
stent, fewer expected SFA reinterventions after the primary
stenting procedure result in net savings.
Keywords Budget impact model  Drug-eluting stent 
Paclitaxel-eluting stent  Peripheral artery disease 
Superficial femoral artery
Introduction
Peripheral artery disease (PAD) is a progressive, lifestyle-
limiting condition with prevalence in the range of 3–10 %,
although it increases to 15–20 % in patients over 70 years
of age [1]. Risk factors such as smoking, obesity, diabetes,
hypertension, and age suggest that the prevalence of PAD
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in modern societies could be increasing [2]. Although most
patients with PAD do not have symptoms, a proportion will
develop symptomatic disease that manifests as pain in the
leg muscles with exercise (intermittent claudication) and
pain at rest, or skin lesions such as ulcers and gangrene
(critical limb ischemia) [1].
Management of PAD is conditioned on a number of
factors such as patient symptoms, patient characteristics
(such as gender, age, smoking, obesity, cardiovascular risk
factors), response to lifestyle and risk factor modification,
and long-term prognosis [3–6]. Bypass surgery has been
widely used to treat patients with critical limb ischemia and
at a risk of limb loss, or those with longer or more compli-
cated lesions. However, as a major surgical procedure, it has
been associated with high morbidity and mortality as well as
considerable resource use [7, 8]. Endovascular therapies are
now commonly used to achieve revascularization in patients
with intermittent claudication or critical limb ischemia
where conservative therapy has not been successful. Within
the endovascular treatment spectrum, percutaneous trans-
luminal balloon angioplasty (PTA) is the simplest and least
resource intensive procedure. PTA is, however, associated
with high 1-year restenosis rates that worsen with longer and
more complex lesions. Reported results vary widely, with
1-year patency rates for PTA ranging from 37 to 80 % [1, 9].
More recently, self-expanding nitinol bare-metal stents
(BMS) have demonstrated improved patency results, yet
restenosis remains a limitation [9–12].
Success in coronary artery intervention has led to
investigation of drug-eluting stents in the superficial fem-
oral artery (SFA). The Zilver PTX drug-eluting stent (Cook
Ireland Ltd., Limerick, Ireland) is a nitinol stent with a
polymer-free paclitaxel coating designed to treat the above-
the-knee femoropopliteal arteries. Zilver PTX was recently
evaluated in a large multicenter, multinational randomized,
controlled trial and a complementary multinational, multi-
center, single-arm clinical study [13–15]. The technology
met the safety (12-month event-free survival) and effec-
tiveness (primary patency) end points in these studies.
Furthermore, results from the Zilver PTX randomized study
demonstrated superior performance compared to PTA and
compared to the identical bare-metal Zilver stent [13].
At a time when health care costs continue to escalate
and budgets are under scrutiny, it is important to under-
stand the impact of new technologies on health care
spending. Whereas some innovations will increase the
overall cost of treating patients, while improving survival
and/or quality of life, the a priori perception that all
innovation adds cost to the system is often the result of a
short-term assessment of the impact on health care budgets,
rather than evaluating the medium- to long-term cost
consequences. The present budget impact assessment was
conducted to inform the reimbursement decision for Zilver
PTX in France. It demonstrates the 5-year budget impact of
a progressive shift from BMS to Zilver PTX.
Materials and Methods
The budget impact model was constructed in Microsoft Excel.
Because the model was originally developed as part of a
reimbursement application to the French national health care
authorities, the perspective is the third-party payer. The impact
on the public health care budget of gradually adopting Zilver
PTX in France was compared to the scenario where only BMS
would be available in situations where stent placement would
be the standard of care, with the model only considering BMS
as a class as opposed to specific BMS types. The published
decision on Zilver PTX reimbursement in France, as with
many other implant devices listed in the French Liste des
Produits et Prestations Remboursables (LPPR), is valid for a
5-year period [16]. Therefore, a 5-year model time horizon
was chosen, with a new patient cohort entering the model each
year from 2012 until 2016. Net budget impact was expressed
as the difference in cost between the scenarios where Zilver
PTX is progressively adopted versus BMS only.
Eligible Population
French national hospital episode statistics from the Agence
Technique de l’Information sur l’Hospitalisation (ATIH)
were used to estimate the patient population [17]. As a first
step, the total number of lower limb peripheral stenting
procedures performed in 2010 was determined [17].
However, the published reimbursement decision states
that Zilver PTX reimbursement should be limited to
patients with symptomatic atherosclerotic occlusive dis-
ease of the lower extremities, when used to treat lesions
(length B14 cm) in the femoropopliteal arteries above the
knee having a reference vessel diameter ranging between 4
and 9 mm, after failure of PTA [18]. Furthermore, the
identified relevant procedure codes describe lower limb
stenting procedures in general, but are not specific to any
one artery in particular. According to the French authori-
ties, the target patient population for SFA stenting with
Zilver PTX was estimated to be about half (48 %) of the
total number of lower limb stenting procedures performed
as per 2008 data [18]. This percentage was applied to the
total number of relevant procedures performed in the latest
year for which ATIH data are available (2010). It was
assumed that the target population would grow at a flat
10 % annual rate in subsequent years, which was informed
by the percentage annual growth in procedures up to 2010.
According to these estimations, the total patient population
eligible for SFA stenting in 2012 is 13,483 patients.
The build-up of the model patient population is summarized
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in Fig. 1. In 2012, the impact of the reimbursement deci-
sion is expected to result in a market penetration rate of
15 %, or 2,022 patients. Moreover, it is expected that the
annual growth rate in adoption of the new technology over
the time horizon of the budget impact model is constant
and equals 5 % per year after 2012, to yield a cumulative
market penetration of 35 % by 2016.
Model Structure
A new cohort of patients eligible for initial stenting enters
the model each year, and patients in that cohort are treated
either with Zilver PTX or BMS. As a result of restenosis of
the treated lesion or lesions, a patient may need a reinter-
vention at some point in time. The model used target lesion
revascularization (TLR) rates for Zilver PTX and BMS in
order to estimate the number of reinterventions and asso-
ciated costs each year. Therefore, for any given year, the
total number of patients needing a reintervention includes
patients who have entered the model in that year as well as
patients who received the initial stenting procedure in a
previous year. The model assumes that a patient is not
eligible for more than one reintervention procedure and
does not die over the 5-year model time horizon. In the
event of needing a reintervention, patients are treated with
one of the following procedures: PTA; stenting or bypass
surgery. The distribution of reintervention options was
estimated on the basis of the observed distribution of
reinterventions from the Zilver PTX single-arm clinical
study, which enrolled 787 patients internationally (Cook
Medical, data on file). The total costs of treating the target
population with Zilver PTX or BMS over 5 years were
compared to the costs of treating the same patient popu-
lation if only BMS were available, in order to assess the
overall budget impact of introducing Zilver PTX in the
French public health care system.
Clinical Data
In the absence of a head-to-head comparison of Zilver PTX
and BMS at the time of model development, the 12- and
24-month TLR rates were extracted from the published
literature on BMS [10, 11, 19] and from 2010 interim data
from the Zilver PTX single-arm clinical study [14]. Interim
data from the single-arm study were used because this was
the trial with the longest-term (24-month) data for TLR and
were the only published data available. Published data on
12-month TLR from the randomized study comparing
safety and effectiveness of Zilver PTX with PTA and
provisional BMS placement in SFA patients [13] were used
in a scenario analysis.
The performance of the Zilver PTX stent was compared
with BMS in the treatment of femoropopliteal lesions on
the basis of published BMS data through subset analyses of
the Zilver PTX single-arm study population data with
matching inclusion/exclusion criteria for each individual
BMS study (Table 1) [14].
All three BMS studies reported 12-month TLR rates [10,
11, 19]. Additionally, the RESILIENT study reported
24-month TLR data [20]. The TLR rates for Zilver PTX in
each of the matching registry subpopulations, based on
interim analysis, were 6 % at 12 months [14]. For BMS, an
average 12-month TLR rate of 16.3 % was calculated
across all three studies to serve as the base case value for
BMS as a class (Table 2). At 24 months, the interim TLR
rate for Zilver PTX was 9 % for the subset of patients
matched with the RESILIENT study (Table 1) [14]. For
BMS, an average 24-month TLR rate of 21.9 % was cal-
culated on the basis of the difference observed between
12- and 24-month TLR rates in the RESILIENT and Zilver
PTX studies (Table 2). More recent 12-month data for the
three matching registry subpopulations indicated lower
TLR rates (4–5 %) for Zilver PTX; thus, the rates used in
Number of lower 
limb stenting
procedures (2010)
EEAF 002:   1,940
EEAF 004:   9,236
EEAF 006:   9,737
EEPF 001:   2,453

















Fig. 1 Build-up of model patient population for SFA stenting
procedures. Classification Commune des Actes Me´dicaux (CCAM)
codes for lower limb stenting procedures [26]: EEAF 002 Percuta-
neous transluminal dilatation of an artery of the lower limb with
transluminal dilatation of the common iliac artery and/or of the
ipsilateral external iliac artery with stent implantation, EEAF 004
Percutaneous transluminal dilatation of an artery of the lower limb
with stent implantation, EEAF 006 Percutaneous transluminal dila-
tation of several arteries of the lower limb with stent implantation
EEPF 001 Percutaneous transluminal recanalization of an artery of
the lower limb with stent implantation
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the model analysis are somewhat higher and therefore
conservatively overestimate the need for reinterventions.
The impact on model results of a reduction in the average
TLR rates for BMS was explored in a scenario analysis
using data for LifeStent from the RESILIENT study, which
at the time of model development was the only study that
reported 12- and 24-month TLR rates [2, 11, 20].
No publications were found reporting the 3-, 4- and
5-year TLR rates after stent implantation. Therefore, those
rates were extrapolated on the basis of clinical expert
opinion that 5 years after initial stent placement, about
40 % of patients treated with BMS would have needed a
reintervention. Absolute annual 6 % increments were
applied to BMS from year 2 onward and the same 6 %
increment after 24 months was also conservatively applied
to the Zilver PTX group because no other data were
available (Table 2). Thus, the clinical benefit of Zilver
PTX is due to the lower TLR rates seen in the first 2 years
after the primary procedure.
Treatment Costs
To reflect the third-party payer’s perspective, only direct
medical costs, covering inpatient treatment, were calcu-
lated. This was based on the reimbursement tariffs for both
Table 1 Literature comparison for TLR rates
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TLR target lesion revascularization, BMS bare-metal stent, Zilver PTX
Zilver PTX drug-eluting stent (Cook Ireland Ltd., Limerick, Ireland)
a TLR rates for Zilver PTX were calculated from matching registry
subset analyses. The inclusion criteria within each of the BMS pub-
lished studies were matched for the Zilver PTX single-arm study [14]
Table 2 TLR and distribution
of reintervention options after
Zilver PTX or BMS
TLR target lesion
revascularization, Zilver PTX
Zilver PTX drug-eluting stent
(Cook Ireland Ltd., Limerick,






Cumulative TLR rate Year 1 6.0 16.3 Zilver PTX: single-arm
study data [14, 15];
BMS: calculated
values
Year 2 9.0 21.9
Year 3 15.0 27.9 Table 1 and expert
opinionYear 4 21.0 33.9
Year 5 27.0 39.9
Type of reintervention PTA 56 Zilver PTX: Cook,
Zilver PTX single-arm





Zilver PTX 25 Expert opinion
BMS 75
If surgical intervention
Synthetic graft 28 Bradbury et al. [21]
Patient’s vein 72
If synthetic graft used,
proportion by type:
Linear or nonlinear textile
implant \30 cm
60 Expert opinion
Linear or nonlinear textile
implant C30 and \70 cm
40
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private and public hospitals, according to the French
Groupe Homoge`ne des Malades (GHM, a national diag-
nosis-related group system) [22] (Table 3). Because vari-
ous GHM tariffs could apply to the episode of care for a
patient requiring lower limb stenting, procedure codes
relevant to lower limb stenting were identified, numbers of
procedures were mapped to specific GHM codes for 2010
[17], and a weighted GHM tariff was calculated, taking
into consideration the proportion of procedures conducted
in public versus private hospitals. Reimbursement fees for
consultants and anesthetists in private hospitals [26] were
also taken into account and added to the respective private
GHM tariff [22]. Costs were based on 2011 reimbursement
tariffs, with variability in key cost inputs explored in sen-
sitivity analyses. Weighted procedure tariffs of PTA and
bypass surgery were calculated by the same methodology.
Key model cost inputs are summarized in Table 3.
As previously mentioned, the expected direct cost of a
reintervention was calculated on the basis of the observed
distribution of reinterventions from the Zilver PTX single-
arm clinical study (Table 2) (Cook Medical, data on file).
The choice of reintervention option is assumed indepen-
dent from the type of stent used for the primary procedure.
Therefore, the expected cost of a reintervention after Zilver
PTX and BMS primary stenting procedures was assumed
the same.
Analyses
In line with principles of good practice for budget impact
analysis, no discounting was applied as the analysis pre-
sents financial streams over time [27]. The impact of
relaxing key assumptions on model results was assessed
through a number of scenario analyses, as summarized in
Table 4.
Results
Under the base case assumptions, the progressive adoption
of Zilver PTX is cost saving from year 1 onward. The
model estimated a cumulative 5-year budget reduction of
Table 3 Model cost inputs
Treatment Cost (€) Source
Zilver PTX 1,000.00 LPPR reimbursement tariff,
code 3141310 [23]




336.61 LPPR reimbursement tariff;
code 3171860 [25]
Linear/nonlinear textile
graft C30 to \70 cm




658.58 LPPR reimbursement tariff;
code 3122608 [25]
Stent implantation 3,082.00 Weighted cost, 2011a
PTA 3,225.00 Weighted cost, 2011b
Surgery 7,414.00 Weighted cost, 2011c
Zilver PTX Zilver PTX drug-eluting stent (Cook Ireland Ltd., Lim-
erick, Ireland), LPPR Liste des Produits et Prestations Rembours-
ables, BMS bare-metal stent, PTA percutaneous transluminal balloon
angioplasty, GHM Groupe Homoge`ne des Malades, MI myocardial
infarction
a Relevant GHM codes are 05K061: vascular stent no MI, level 1;
05K062: vascular stent no MI, level 2; 05K063: vascular stent no MI,
level 3; 05K064: vascular stent no MI, level 4; 05K06T: vascular stent
no MI, very short stay 0 or 1 day [22]
b Relevant GHM codes are 05K131: Endovascular procedures without
stent, age above 17 years, level 1; 05K132: Endovascular procedures
without stent, age above 17 years, level 2; 05K133: Endovascular
procedures without stent, age above 17 years, level 3; 05K134: Endo-
vascular procedures without stent, age above 17 years, level 4;
05K13 J: Endovascular procedures without stent, age above 17 years,
ambulatory [22]
c Relevant GHM codes are 05C101: Major vascular surgery, level 1;
05C102: Major vascular surgery, level 2; 05C103: Major vascular
surgery, level 3; 05C104: Major vascular surgery, level 4 [22]
Table 4 Scenario analyses
Variable Scenario
Higher TLR rates after Zilver PTX
stenting
12-month TLR 9.5 % [13]
24-month TLR 12.5 %
(estimated)
Lower TLR rates after BMS stenting 12-month TLR 12.7 %
[12, 19]
24-month TLR 20.0 % [20]
Zilver PTX market share at year 5 2012: 10 % to 2016: 30 %
30 % reduction in costs for primary
stenting procedure and reintervention
Primary stenting: €2,158;
reintervention: €2,774
30 % increase in costs for primary
stenting procedure and reintervention
Primary stenting: €4,007;
reintervention: €5,151
Increased number of Zilver PTX stents
for primary stenting procedure
1.25a
Zilver PTX market share at year 5 2012: 20 % to 2016:
40.53 %b
8 % reduction in Zilver PTX and BMS
tariffs
Zilver PTX: €920c; BMS:
€774.20 (estimated)
TLR target lesion revascularization, Zilver PTX Zilver PTX drug-
eluting stent (Cook Ireland Ltd., Limerick, Ireland), BMS bare-metal
stent
a This assumes that a maximum of 25 % of cases would require two
stents within this population, where the maximum lesion length is
14 cm
b To reach target population of 8,000 in 2016, in accordance with
target population for Zilver PTX as defined by French authorities [18]
c In accordance with fixed tariff from March 30, 2013, onward as
defined by French authorities [23]
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€6,807,202 for a projected population of 82,316 patients, of
which 21,361 received the Zilver PTX stent (Table 5).
The difference in stent cost between Zilver PTX and
BMS is more than offset by the savings accruing from
lower reintervention rates, and therefore less rehospitali-
zation, in each of the 5 years after the primary procedure
(Fig. 2). The model calculated that 2,572 reintervention
events would be avoided over 5 years with the progressive
adoption of Zilver PTX (or a reduction from 22,088 to
19,516 events). For a hypothetical patient starting treat-
ment in 2012, estimated total cost, including primary
stenting and expected reinterventions up to 5 years, was
€5,503 when a BMS was used, compared to €5,152 with
Zilver PTX (difference of €351).
Scenario analyses indicated that the adoption of Zilver
PTX results in cumulative 5-year budget reduction
regardless of scenario (Fig. 3). Increasing the average
number of Zilver PTX stents to 1.25 per patient for primary
stenting yields the lowest net budget reduction. Although
the use of lower TLR rates for BMS or higher 12-month
TLR rates for Zilver PTX decreases budget savings in each
year, 5-year cumulative budget offsets remain substantial.
Faster uptake of Zilver PTX further increases annual
budget savings because of the expected increased reduction
in reinterventions. Similarly, the higher the primary stent-
ing and expected reintervention cost, the higher are the
budget savings associated with the use of Zilver PTX. To
illustrate, increased costs could result from a larger share of
bypass surgery reinterventions, or the need for some
patients to undergo two angioplasty procedures for in-stent
restenosis, leading to higher hospitalization costs.
Discussion
In September 2011, the French government published its
decision to reimburse Zilver PTX [23] at €1,000 per stent, a
19 % premium over the BMS reimbursement level. A
higher tariff could suggest that this new technology would
result in increased health care spending. However, as this
budget impact analysis demonstrates, the expected reduc-
tions in restenosis and TLR rates not only provide clinical
benefit to patients, but also help to avoid costly rehospi-
talization. The model suggests that budget offsets start
within the first year of adoption and are sustained over the
5-year model time horizon.
Zilver PTX has demonstrated reductions in restenosis
and TLR rates compared to the more traditional treatments
of PTA and/or BMS [10, 11, 13–15, 19, 20]. This is an
important clinical breakthrough in the treatment of ath-
erosclerotic SFA disease. In today’s health care environ-
ment of ever-increasing demands on limited financial
resources, health care decision makers—physicians, pay-
ers, and patients—increasingly want to understand the
economic ramifications of new technologies. More and
more, the questions being asked are ‘‘is it worth it?’’ and if
so, ‘‘at what cost?.’’
Table 5 Total and net 5-year budget impact








No. of procedures with







Year 1 (2012) 13,483 61,632,893 2,022 (15 %) 11,461 61,125,303 -507,590 (-0.8 %)
Year 2 (2013) 14,832 70,748,351 2,966 (20 %) 11,865 69,801,480 -946,871 (-1.3 %)
Year 3 (2014) 16,315 81,028,788 4,079 (25 %) 12,236 79,708,287 -1,320,502 (-1.6 %)
Year 4 (2015) 17,946 92,337,269 5,384 (30 %) 12,562 90,577,880 -1,759,389 (-1.9 %)
Year 5 (2016) 19,741 104,776,598 6,909 (35 %) 12,832 102,503,749 -2,272,850 (-2.2 %)
Total over 5 years 82,316 410,523,900 21,361 (26 %) 60,956 403,716,697 -6,807,202 (-1.7 %)
Values are undiscounted; minus sign signifies reduction in annual budget
Zilver PTX Zilver PTX drug-eluting stent (Cook Ireland Ltd., Limerick, Ireland), BMS bare-metal stent







reduction in reintervention costs incremental stent cost
Fig. 2 Net budget impact by year with Zilver PTX scenario versus
BMS only. A minus sign indicates budget reduction; a plus sign
indicates budget increase
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There have been some attempts to assess the costs of
treating patients with PAD. Mahoney et al. [2] compared
the 2-year rates of vascular-related hospitalizations and
associated costs in US patients with established PAD
across patient subgroups. They concluded that the eco-
nomic burden of PAD is high as a result of recurring
hospitalizations and repeat revascularization procedures. A
health care cost utilization study in the United States [28]
attempted to assess the cost per day of patency after vas-
cular reconstruction, and to determine if the initial cost
savings of endovascular procedures were sustained over
time. Although it concluded that the initial cost savings of
endovascular therapies were not sustained, this analysis
was limited to a 12-month time horizon and bundled all
endovascular modalities (angioplasty, stenting, atherec-
tomy or cryoplasty) into one group. The study was also
limited by its retrospective nature and moderate sample
size. In 2010, the authors of a review article on new SFA
treatments [29] presented a hypothetical cost-calculation
comparing the costs of using non-drug-eluting stents with
drug-eluting stents. Although the review acknowledged the
promise shown by preliminary clinical data for Zilver PTX,
the cost analysis suggested that the stent would have an
additional economic burden at 12 months after the proce-
dure. However, the review has a number of limitations:
(1) the underlying assumptions and methodology are
unclear; (2) the sources for the hypothetical stent costs as
well as for the reintervention profiles considered are not
disclosed; and (3) the review used patency rates to calcu-
late the number of repeat revascularization procedures,
despite TLR rates being the more appropriate outcome.
As with any model, varying degrees of uncertainty exist
around key model inputs. Model parameters were derived
from previously reported studies and clinical trial data,
supplemented by expert clinical opinion where published
evidence was not available. Some of these uncertainties
were: (1) the lack of randomized controlled trials directly
comparing TLR rates of the Zilver PTX stent and current
generation BMS; (2) the absence of long-term comparative
results; (3) the assumption that the reintervention distri-
bution was constant over time; (4) assumptions surround-
ing the number of stents used per SFA stenting procedure
and the rate of uptake of Zilver PTX in France; and (5) the
future level of GHM and LPPR tariffs. However, the
uncertainties around the above parameters were addressed
by conducting scenario analyses, the results of which
confirmed the robustness of the model base case.
Like any other modelling study, which aims to reflect a
complex real-world situation, this model has limitations.
Firstly, the model population is restricted to the subgroup
of lower limb atherosclerosis patients and shorter lesions
(length B14 cm) and a reference vessel diameter between 4
and 9 mm, as per the French authority decision [18]. This
may not allow extrapolation to other populations. Indeed,
the analysis does not assess budget impact for patient
populations with longer, more difficult lesions nor for
Zilver PTX as a first-line treatment for diabetic patients and
in-stent restenosis. Because it is particularly challenging to
treat these subgroups of patients [30–33], it would be
interesting to study the budget impact of the use of Zilver
PTX in a wider population when more clinical evidence for
such patients becomes available. Furthermore, the model
only considers the patient population that is eligible for
stenting and does not include populations where other
treatments such as balloon angioplasty or bypass surgery
are the standard of care. Although the analysis performed is
-€12-€10-€8-€6-€4-€2€0
Higher TLR rates af ter Zilver PTX stenting
Lower TLR rates af ter BMS stenting
Zilver PTX 30.00% market share at year 5
30% reduction in costs
30% increase in costs
Increased number of  Zilver PTX stents
Zilver PTX 40.53% market share at year 5






Fig. 3 Five-year net budget
impact with Zilver PTX
scenario versus BMS only
compared to base case. Scenario
descriptions correspond with
those in Table 4
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specific to the impact of switching from BMS to Zilver
PTX when treating femoropopliteal disease, there are also
other new treatments that may be interesting to consider
from a budget impact perspective, such as drug-eluting
balloons [34].
Secondly, the model base case does not use randomized
controlled trial data to compare TLR rates between groups.
Although such data offer a higher level of evidence than
single-arm study data, these were not available at the time
of model development when only 12-month TLR rates
were published for the primary stenting arm in the Zilver
PTX randomized study (TLR = 9.5 %) [13]. This was
used in a scenario analysis, and results were not much
different compared to the base case. A 24-month update on
the Zilver PTX randomized study reported 12- and
24-month TLR rates for the secondary randomization of
provisional Zilver PTX versus provisional BMS, both after
failed PTA (12-month TLR of 5.3 vs. 17.6 % and
24-month TLR of 10.8 vs. 23.1 %, respectively) [35]. The
difference in 24-month TLR rates for provisional Zilver
PTX and provisional BMS reported for the randomized
study is very similar to the difference in the TLR rates from
the interim analysis used in the budget impact model,
which further strengthens the validity of the results.
Thirdly, in the absence of any long-term evidence
(beyond 24 months), TLR rates for years 3, 4, and 5 were
extrapolated assuming a constant 6 % absolute increase,
which was informed by expert opinion estimating a
cumulative 40 % TLR rate after primary stenting with
BMS after 5 years. The validity of this assumption is
confirmed by the recently published 3-year follow-up
results from the RESILIENT trial, which indicated freedom
from TLR of 75.5 % in the BMS group (equivalent to
24.5 % TLR compared to base case model average 3-year
TLR of 27.9 %) [36].
Lastly, the model does not take into account mortality,
as there was no clinical evidence suggesting a difference in
survival between Zilver PTX and BMS. This has negligible
impact on the reported budget reduction because the dif-
ference in cost between Zilver PTX and BMS groups is
expected to remain constant with equal mortality.
Results from this study lend support to the argument that
adoption of a somewhat more costly new technology can
improve clinical outcomes while reducing expenditure,
making both clinical and economic sense for the health
care system to adopt the technology. To realize these
benefits, it requires payers’ willingness to take a longer-
term view of spending. It also demands that researchers and
manufacturers involved with developing technology
appreciate that health care budgets are not unlimited. These
challenges can be met by both payers and manufacturers,
as seen here with the adoption of the Zilver PTX stent in
France, resulting in a reimbursement decision that can
minimize financial hurdles for providers adopting the
technology, ultimately benefiting the French patient.
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